---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-25-000004"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:49:41.417866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3

## Summary
- Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.
- R&D expenses rose to $112.8M in 2024 from $31.8M in 2023 as Phase 3 trials for HS and PsA started.
- Cash and equivalents of $448.0M as of Dec 31, 2024, down from $493.9M in Q3 2024; runway to end of 2026.
- Initiated Phase 3 VELA (HS), Phase 3 IZAR (PsA), plus Phase 2 trials in PPP, axSpA, and adolescent HS.
- Capital Markets Update planned for Q2 2025 to discuss Phase 3 HS data and financials.

## SEC filing metadata
- accession: 0001821586-25-000004
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/0001821586-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/mnlk-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-25-000004
- JSON: https://secwatch.observer/filing/0001821586-25-000004.json
- Plain text: https://secwatch.observer/filing/0001821586-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.